» Articles » PMID: 26482468

Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report

Overview
Journal Am J Case Rep
Specialty General Medicine
Date 2015 Oct 21
PMID 26482468
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Type 2 diabetes is a well described extra-hepatic manifestation of hepatitis C infection (HCV). Eradication of HCV has led to improvements in insulin resistance but to date has not been shown to induce remission of diabetes.

Case Report: We report a case of a 49-year-old man with HCV and a 2-year history of T2DM on oral agents. He was initially treated with peg-interferon/ribavirin (peg-IFN/rib) but did not achieve a HCV treatment response. Four years later he was retreated with peg-IFN/rib plus an HCV protease inhibitor (boceprevir). His HbA1c at the start of treatment was 7.9%. Antiviral response to HCV-therapy correlated with a significant improvement in glucose control without a change in diabetes therapy or improvement in adherence. He achieved a sustained virological response and within a year of completing antiviral therapy he no longer required medical therapy for diabetes. Two years after the completion of HCV treatment, the patient has maintained an HbA1c of 5.8% without any diabetes medications.

Conclusions: This case provides evidence of the important relationship between HCV and diabetes and highlights the potential reversibility of glucose abnormalities with successful eradication of HCV. Increased awareness of this association may improve detection of undiagnosed HCV infection, identify patients with reversible causes of diabetes, guide therapeutic decisions for HCV treatment, and improve outcomes in patients with both diseases.

Citing Articles

The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis.

Hung H, Lai H, Lin H, Chen C Ann Med. 2023; 55(1):463-479.

PMID: 36655629 PMC: 9858431. DOI: 10.1080/07853890.2023.2168745.


Association between hepatitis C antiviral treatment and diabetes mellitus: A case series.

Zhang J, Cooper C, Doyle M J Assoc Med Microbiol Infect Dis Can. 2022; 5(2):104-110.

PMID: 36338185 PMC: 9602886. DOI: 10.3138/jammi-2019-0007.


Anti-diabetics and antimicrobials: Harmony of mutual interplay.

Hegazy W, Rajab A, Lila A, Abbas H World J Diabetes. 2021; 12(11):1832-1855.

PMID: 34888011 PMC: 8613656. DOI: 10.4239/wjd.v12.i11.1832.


Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.

Iliescu E, Mercan-Stanciu A, Toma L BMC Nephrol. 2020; 21(1):21.

PMID: 31948406 PMC: 6966843. DOI: 10.1186/s12882-020-1687-1.


A SEVERE CASE OF HYPERGLYCEMIA IN A KIDNEY TRANSPLANT RECIPIENT UNDERGOING INTERFERON-FREE THERAPY FOR CHRONIC HEPATITIS C.

Iliescu L, Mercan-Stanciu A, Toma L, Ioanitescu E Acta Endocrinol (Buchar). 2019; 14(4):533-538.

PMID: 31149309 PMC: 6516407. DOI: 10.4183/aeb.2018.533.


References
1.
Walsh M, Jonsson J, Richardson M, Lipka G, Purdie D, Clouston A . Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2005; 55(4):529-35. PMC: 1856185. DOI: 10.1136/gut.2005.069674. View

2.
Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T . Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004; 165(5):1499-508. PMC: 1618659. DOI: 10.1016/S0002-9440(10)63408-6. View

3.
Taura N, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T . Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol. 2006; 101(12):2752-9. DOI: 10.1111/j.1572-0241.2006.00835.x. View

4.
Chen T, Huang P, Tsai M, Lin L, Liu C, Ho K . Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007; 22(5):669-75. DOI: 10.1111/j.1440-1746.2007.04898.x. View

5.
Huang J, Dai C, Hwang S, Ho C, Hsiao P, Hsieh M . Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007; 102(6):1237-43. DOI: 10.1111/j.1572-0241.2007.01181.x. View